Evidence map›Paper›PMID 39861790›Full record

ReviewViruses2024

Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.

Thomas J Baric, Z Beau Reneer

Abstract readReview
In one paragraph

Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas J BaricDepartment of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3500, USA.
Z Beau ReneerDepartment of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3500, USA.ORCID 0000-0002-5685-000X

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5M
Project 5: mAb Development Flaviviruses and AlphavirusesU19AI181960 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, KUHN, RICHARD J. · 2024 to 2024
$46.7M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniela Weiskopf · 2015 to 2026
$34.1M
NIAID NIH HHS P01 AI106695NIAID NIH HHS U19 AI171292NIAID NIH HHS U19 AI181960
6 · The paper itself

Abstract

Flaviviruses are arthropod-borne viruses primarily transmitted through the mosquito

Indexed as

Communicable Diseases, EmergingDisease Models, AnimalFlavivirusFlavivirus InfectionsViral VaccinesAnimalsHumansMiceViral Vaccinesanimal modelsdengue virusflavivirusPowassan virustherapeuticstick-borne encephalitis virusUsutu virusvaccinesWest Nile virusyellow fever virusZika virus

Identifiers

PMID39861790
PMCPMC11769264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.